Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Novartis winds down ph. 1 solid tumor program due to lack of efficacy

Novartis winds down ph. 1 solid tumor program due to lack of efficacy

  • February 19, 2026

Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients with advanced disease.

Leave A Comment

Fields (*) Mark are Required